Business
Leading cancer centre publishes Parsortix workflow
Leading cancer centre publishes Parsortix workflow.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 7188L\n Angle PLC\n 04 May 2020\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 4 May 2020\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n LEADING CANCER CENTRE PUBLISHES PARSORTIX WORKFLOW ADDRESSING PROBLEMS WITH ALTERNATIVE APPROACHES\n \n \n \n \n \n Workflow for RNA gene expression demonstrated in prostate cancer\n \n \n \n \n \n Researchers show that \"previously undetectable prostate specific transcripts become readily measurable\"\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Southern California has published results of new work undertaken in advanced prostate cancer demonstrating a workflow developed using ANGLE's Parsortix® system to provide rapid circulating tumor cell (CTC) enrichment and transcriptomic profiling in prostate cancer that is scalable in a cost effective way to large numbers of patient blood samples.\n \n \n \n \n \n Transcriptomic profiling is the process by which cancer cells, in this case harvested by Parsortix from a simple blood test, are analysed to determine their RNA gene expression to identify how the patient's cancer is developing and evading the immune system so that decisions can be made as to which drug treatments may be most effective for that patient at that time. Standard tissue biopsy is invasive and reflects only a single metastatic site at a single point in time, whereas CTC analyses may reflect multiple metastatic sites and are repeatable allowing the dynamic nature of the cancer to be profiled. This approach enables personalised medicine and addresses the major problem of identifying the right drug at the right time as most drugs only work for a proportion of patients and a \"one size fits all\" approach is limited in its effectiveness.\n \n \n \n \n \n The researchers identified key advantages of their Parsortix-based workflow compared to other CTC approaches, as follows: \n \n \n \n \n \n · \n high enrichment levels (high purity of cancer cells with low levels of contaminating white blood cells) for detection of cancer-specific genes over background noise allowing previously undetectable prostate specific transcripts to become readily measurable; \n \n \n ...